{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T00:02:18Z","timestamp":1789603338846,"version":"build-2803163510"},"reference-count":56,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T00:00:00Z","timestamp":1783987200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004608","name":"Jiangsu Province Natural Science Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004608","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.apsb.2026.07.022","type":"journal-article","created":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T23:18:06Z","timestamp":1784330286000},"page":"6235-6252","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Photothermal-driven sequential immunotherapy overcomes resistance to PARP inhibition in Brca1-deficient triple-negative breast cancer"],"prefix":"10.1016","volume":"16","author":[{"given":"Zhenyu","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shengyi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiyang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianing","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yinghuan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xulin","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ya","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haodi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiasheng","family":"Tu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qian","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6588-6047","authenticated-orcid":false,"given":"Chunmeng","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.07.022_bib1","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1056\/NEJMra1001389","article-title":"Triple-negative breast cancer","volume":"363","author":"Foulkes","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.07.022_bib2","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","article-title":"Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease","volume":"13","author":"Bianchini","year":"2016","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib3","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1038\/s41467-022-30568-1","article-title":"STING agonism reprograms tumor-associated macrophages and overcomes resistance to PARP inhibition in Brca1-deficient models of breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.07.022_bib4","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1093\/annonc\/mdz012","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib5","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1016\/j.annonc.2020.08.2098","article-title":"Talazoparib versus chemotherapy in patients with germline BRCA1\/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial","volume":"31","author":"Litton","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib6","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1038\/s41523-022-00468-0","article-title":"Triple negative breast cancer: pitfalls and progress","volume":"8","author":"Zagami","year":"2022","journal-title":"NPJ Breast Cancer"},{"key":"10.1016\/j.apsb.2026.07.022_bib7","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/s41568-024-00714-6","article-title":"Towards targeting the breast cancer immune microenvironment","volume":"24","author":"Harris","year":"2024","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.07.022_bib8","first-page":"869","article-title":"New insight into targeting the DNA damage response in the treatment of glioblastoma","volume":"22","author":"Zhen","year":"2024","journal-title":"Chin J Nat Med"},{"key":"10.1016\/j.apsb.2026.07.022_bib9","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jamaoncol.2018.4224","article-title":"Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study","volume":"5","author":"Emens","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib10","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1001\/jamaoncol.2019.1029","article-title":"Open-label clinical trial of niraparib combined with pembrolizumab for treatment of advanced or metastatic triple-negative breast cancer","volume":"5","author":"Vinayak","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib11","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1016\/j.apsb.2025.05.039","article-title":"Engineering strategies of sequential drug delivery systems for combination tumor immunotherapy","volume":"15","author":"Xu","year":"2025","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.07.022_bib12","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.jconrel.2022.04.015","article-title":"A bio-responsive, cargo-catchable gel for postsurgical tumor treatment via ICD-based immunotherapy","volume":"346","author":"Chen","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.07.022_bib13","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1016\/j.jconrel.2022.09.006","article-title":"Sequentially sustained release of anticarcinogens for postsurgical chemoimmunotherapy","volume":"350","author":"Chen","year":"2022","journal-title":"J Control Release"},{"key":"10.1016\/j.apsb.2026.07.022_bib14","doi-asserted-by":"crossref","first-page":"4195","DOI":"10.1016\/j.apsb.2024.06.026","article-title":"Pyroptosis: induction and inhibition strategies for immunotherapy of diseases","volume":"14","author":"Wu","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.07.022_bib15","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S1470-2045(20)30324-7","article-title":"Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1\/2, basket study","volume":"21","author":"Domchek","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib16","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1001\/jamaoncol.2019.1048","article-title":"Single-arm phases 1 and 2 trial of niraparib in combination with pembrolizumab in patients with recurrent platinum-resistant ovarian carcinoma","volume":"5","author":"Konstantinopoulos","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib17","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","article-title":"Treatment landscape of triple-negative breast cancer-expanded options, evolving needs","volume":"19","author":"Bianchini","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib18","doi-asserted-by":"crossref","first-page":"2815","DOI":"10.1016\/j.apsb.2024.04.020","article-title":"Therapeutic strategies of targeting non-apoptotic regulated cell death (RCD) with small-molecule compounds in cancer","volume":"14","author":"Jin","year":"2024","journal-title":"Acta Pharm Sin B"},{"key":"10.1016\/j.apsb.2026.07.022_bib19","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1038\/nrd.2018.169","article-title":"Targeting macrophages: therapeutic approaches in cancer","volume":"17","author":"Cassetta","year":"2018","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.apsb.2026.07.022_bib20","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1038\/s41568-022-00547-1","article-title":"A timeline of tumour-associated macrophage biology","volume":"23","author":"Cassetta","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.07.022_bib21","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib22","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/j.cell.2023.02.020","article-title":"Macrophages at the interface of the co-evolving cancer ecosystem","volume":"186","author":"Kloosterman","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.07.022_bib23","first-page":"1089","article-title":"Glycyrrhizic acid-based multifunctional nanoplatform for tumor microenvironment regulation","volume":"22","author":"Xiao","year":"2024","journal-title":"Chin J Nat Med"},{"key":"10.1016\/j.apsb.2026.07.022_bib24","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.07.022_bib25","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.583084","article-title":"Tumor-associated macrophages in tumor immunity","volume":"11","author":"Pan","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.07.022_bib26","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s43018-020-00148-7","article-title":"Targeting immunosuppressive macrophages overcomes PARP inhibitor resistance in Brca1-associated triple-negative breast cancer","volume":"2","author":"Mehta","year":"2021","journal-title":"Nat Cancer"},{"key":"10.1016\/j.apsb.2026.07.022_bib27","doi-asserted-by":"crossref","first-page":"846","DOI":"10.1016\/j.ccr.2014.05.016","article-title":"Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy","volume":"25","author":"Ries","year":"2014","journal-title":"Cancer Cell"},{"key":"10.1016\/j.apsb.2026.07.022_bib28","doi-asserted-by":"crossref","first-page":"5057","DOI":"10.1158\/0008-5472.CAN-13-3723","article-title":"CSF1\/CSF1R blockade reprograms tumor-infiltrating macrophages and improves response to T-cell checkpoint immunotherapy in pancreatic cancer models","volume":"74","author":"Zhu","year":"2014","journal-title":"Cancer Res"},{"key":"10.1016\/j.apsb.2026.07.022_bib29","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1158\/1078-0432.CCR-14-1845","article-title":"An open-label, multicenter, phase I\/II study of JNJ-40346527, a CSF-1R inhibitor, in patients with relapsed or refractory Hodgkin lymphoma","volume":"21","author":"von Tresckow","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.07.022_bib30","article-title":"Local exosome inhibition potentiates mild photothermal immunotherapy against breast cancer","volume":"12","author":"Chen","year":"2025","journal-title":"Adv Sci (Weinh)"},{"key":"10.1016\/j.apsb.2026.07.022_bib31","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.immuni.2020.04.011","article-title":"The CD47\u2013SIRP\u03b1 immune checkpoint","volume":"52","author":"Logtenberg","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2026.07.022_bib32","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1111\/imr.12527","article-title":"The CD47\u2013SIRP\u03b1 signaling axis as an innate immune checkpoint in cancer","volume":"276","author":"Matlung","year":"2017","journal-title":"Immunol Rev"},{"key":"10.1016\/j.apsb.2026.07.022_bib33","doi-asserted-by":"crossref","first-page":"1209","DOI":"10.1038\/nm.3931","article-title":"CD47 blockade triggers T cell\u2013mediated destruction of immunogenic tumors","volume":"21","author":"Liu","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.apsb.2026.07.022_bib34","doi-asserted-by":"crossref","first-page":"11103","DOI":"10.1073\/pnas.1305569110","article-title":"Anti-CD47 antibody-mediated phagocytosis of cancer by macrophages primes an effective antitumor T-cell response","volume":"110","author":"Tseng","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.07.022_bib35","doi-asserted-by":"crossref","first-page":"E2646","DOI":"10.1073\/pnas.1604268113","article-title":"Durable antitumor responses to CD47 blockade require adaptive immune stimulation","volume":"113","author":"Sockolosky","year":"2016","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.07.022_bib36","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.89140","article-title":"Anti-SIRP\u03b1 antibodies as a potential new tool for cancer immunotherapy","volume":"2","author":"Yanagita","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.apsb.2026.07.022_bib37","doi-asserted-by":"crossref","first-page":"4871","DOI":"10.1038\/s41467-019-12771-9","article-title":"Mild photothermal therapy potentiates anti-PD-L1 treatment for immunologically cold tumors via an all-in-one and all-in-control strategy","volume":"10","author":"Huang","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.07.022_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0169-409X(96)00491-7","article-title":"Solubilisation of hydrophilic drugs in oily formulations","volume":"25","author":"New","year":"1997","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.apsb.2026.07.022_bib39","doi-asserted-by":"crossref","first-page":"5858","DOI":"10.1074\/jbc.273.10.5858","article-title":"DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139","volume":"273","author":"Rogakou","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.apsb.2026.07.022_bib40","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1038\/nature14156","article-title":"Mitochondrial DNA stress primes the antiviral innate immune response","volume":"520","author":"West","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.07.022_bib41","article-title":"Mitochondrion-targeted type I photodynamic therapy for agonist independent cGAS\u2013STING activation","volume":"37","author":"Xu","year":"2025","journal-title":"Adv Mater"},{"key":"10.1016\/j.apsb.2026.07.022_bib42","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1038\/s41392-023-01624-z","article-title":"The cGAS\u2013STING pathway-dependent sensing of mitochondrial DNA mediates ocular surface inflammation","volume":"8","author":"Ouyang","year":"2023","journal-title":"Signal Transduct Target Ther"},{"key":"10.1016\/j.apsb.2026.07.022_bib43","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1016\/j.tcb.2024.02.006","article-title":"ER: a critical hub for STING signaling regulation","volume":"34","author":"Luo","year":"2024","journal-title":"Trends Cell Biol"},{"key":"10.1016\/j.apsb.2026.07.022_bib44","article-title":"STING, the endoplasmic reticulum, and mitochondria: is three a crowd or a conversation?","volume":"11","author":"Smith","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.07.022_bib45","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1021\/acsnano.2c10797","article-title":"Blood clot scaffold loaded with liposome vaccine and siRNAs targeting PD-L1 and TIM-3 for effective DC activation and cancer immunotherapy","volume":"17","author":"Chen","year":"2022","journal-title":"ACS Nano"},{"key":"10.1016\/j.apsb.2026.07.022_bib46","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/j.immuni.2022.12.002","article-title":"CD8+ T cell activation in cancer comprises an initial activation phase in lymph nodes followed by effector differentiation within the tumor","volume":"56","author":"Prokhnevska","year":"2023","journal-title":"Immunity"},{"key":"10.1016\/j.apsb.2026.07.022_bib47","doi-asserted-by":"crossref","first-page":"eabg7836","DOI":"10.1126\/sciimmunol.abg7836","article-title":"A reservoir of stem-like CD8+ T cells in the tumor-draining lymph node preserves the ongoing antitumor immune response","volume":"6","author":"Connolly","year":"2021","journal-title":"Sci Immunol"},{"key":"10.1016\/j.apsb.2026.07.022_bib48","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","article-title":"Systemic immunity in cancer","volume":"21","author":"Hiam-Galvez","year":"2021","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.apsb.2026.07.022_bib49","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1200\/JCO.2004.04.179","article-title":"Incidence of BRCA1 and BRCA2 mutations in young Korean breast cancer patients","volume":"22","author":"Choi","year":"2004","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib50","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.trecan.2021.05.004","article-title":"Development of poly(ADP-ribose) polymerase inhibitor and immunotherapy combinations: progress, pitfalls, and promises","volume":"7","author":"Pham","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.apsb.2026.07.022_bib51","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1158\/1078-0432.CCR-23-2513","article-title":"Phase II DORA study of olaparib with or without durvalumab as a chemotherapy-free maintenance strategy in platinum-pretreated advanced triple-negative breast cancer","volume":"30","author":"Tan","year":"2024","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.07.022_bib52","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/jamaoncol.2022.5218","article-title":"Avelumab plus talazoparib in patients with BRCA1\/2- or ATM-altered advanced solid tumors: results from JAVELIN BRCA\/ATM, an open-label, multicenter, phase 2b, tumor-agnostic trial","volume":"9","author":"Schram","year":"2023","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib53","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1016\/S1470-2045(19)30396-1","article-title":"Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a\/b trial","volume":"20","author":"Friedlander","year":"2019","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.apsb.2026.07.022_bib54","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","article-title":"First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial","volume":"398","author":"Janjigian","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.07.022_bib55","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.07.022_bib56","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s40820-021-00647-x","article-title":"Time-programmed delivery of Sorafenib and anti-CD47 antibody via a double-layer-gel matrix for postsurgical treatment of breast cancer","volume":"13","author":"Huang","year":"2021","journal-title":"Nano-Micro Lett"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004600?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526004600?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T23:13:14Z","timestamp":1789600394000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526004600"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":56,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2211383526004600"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.07.022","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Photothermal-driven sequential immunotherapy overcomes resistance to PARP inhibition in Brca1-deficient triple-negative breast cancer","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.07.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}